A068760 Stock Overview
A pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Celltrion Pharm, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩53,200.00 |
| 52 Week High | ₩114,095.24 |
| 52 Week Low | ₩47,238.10 |
| Beta | 0 |
| 1 Month Change | -6.17% |
| 3 Month Change | -8.43% |
| 1 Year Change | -46.55% |
| 3 Year Change | -29.13% |
| 5 Year Change | 50.12% |
| Change since IPO | 385.74% |
Recent News & Updates
Does Celltrion Pharm (KOSDAQ:068760) Deserve A Spot On Your Watchlist?
May 05
Do Institutions Own Celltrion Pharm, Inc. (KOSDAQ:068760) Shares?
Mar 03These 4 Measures Indicate That Celltrion Pharm (KOSDAQ:068760) Is Using Debt Reasonably Well
Feb 02
Recent updates
Does Celltrion Pharm (KOSDAQ:068760) Deserve A Spot On Your Watchlist?
May 05Do Institutions Own Celltrion Pharm, Inc. (KOSDAQ:068760) Shares?
Mar 03These 4 Measures Indicate That Celltrion Pharm (KOSDAQ:068760) Is Using Debt Reasonably Well
Feb 02Do Celltrion Pharm's (KOSDAQ:068760) Earnings Warrant Your Attention?
Dec 29Celltrion Pharm, Inc.'s (KOSDAQ:068760) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Nov 24Shareholder Returns
| A068760 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -0.6% | 0.4% | -0.7% |
| 1Y | -46.5% | 10.0% | -5.5% |
Return vs Industry: A068760 underperformed the KR Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: A068760 underperformed the KR Market which returned -2.2% over the past year.
Price Volatility
| A068760 volatility | |
|---|---|
| A068760 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A068760 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A068760's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | n/a | Jung-su Seo | www.celltrionph.com |
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies.
Celltrion Pharm, Inc. Fundamentals Summary
| A068760 fundamental statistics | |
|---|---|
| Market cap | ₩2.31t |
| Earnings (TTM) | ₩26.03b |
| Revenue (TTM) | ₩274.73b |
0.0x
P/E Ratio0.0x
P/S RatioIs A068760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A068760 income statement (TTM) | |
|---|---|
| Revenue | ₩274.73b |
| Cost of Revenue | ₩193.89b |
| Gross Profit | ₩80.84b |
| Other Expenses | ₩54.82b |
| Earnings | ₩26.03b |
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A068760 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 09:09 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Celltrion Pharm, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | iM Securities |
| Sanghwa Lee | KB Securities Co., Ltd. |
| Heajin Kim | Morgan Stanley |